Literature DB >> 2979758

Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).

B Winograd1, E Boven, M W Lobbezoo, H M Pinedo.   

Abstract

In an attempt to increase the predictability of preclinical antitumor testing, the value of human tumor lines in immune-deficient nude mice is assessed by reviewing the relevant literature. This test model is rather elaborate due to the nature of the animal as well as test and evaluation procedure. However, it represents a realistic simulation of clinical drug treatment. This is demonstrated by (a) a good correlation of drug effects in the nude mouse with clinical results in the donating patient's tumor and (b) by a good predictability of a panel of human tumor lines for clinically effective drugs. In order to avoid clinical trials with inactive drugs and no therapeutic benefit for a large number of patients, the application of human tumor xenografts in anticancer drug development is warranted.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2979758

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  5 in total

1.  Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

Authors:  B J Braakhuis; G A van Dongen; M van Walsum; A Leyva; G B Snow
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

2.  Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice.

Authors:  H Naundorf; I Fichtner; G J Saul; W Haensch; B Büttner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.

Authors:  Y Naoe; M Inami; S Matsumoto; S Takagaki; T Fujiwara; S Yamazaki; I Kawamura; F Nishigaki; S Tsujimoto; T Manda; K Shimomura
Journal:  Jpn J Cancer Res       Date:  1998-12

4.  Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.

Authors:  G J Peters; B J Braakhuis; E A de Bruijn; E J Laurensse; M van Walsum; H M Pinedo
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

5.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

Authors:  E Boven; H Schipper; C A Erkelens; S A Hatty; H M Pinedo
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.